Here we report a retrospective analysis performed to evaluate the results of autologous hematopoietic stem cell transplantation in pediatric patients with Hodgkin Disease (HD) in a single center in Bogota, Colombia.Nineteen patients with relapsed or refractory HD underwent autologous stem cell transplantation between 1998 and 2006. 8 female/11 male, with mean age of 10.9 years (7–14). At diagnosis patients were staged: I and IIA 10, IIB 1, IIIA 1, IIIB 4 and stage IV 6. The response to first line therapy was: 8 patients had failure to induction, and 6 early relapse (before 12 months). At transplantation: 10 patients were in 2nd complete remission, 2 in 3th complete remission and 7 were in partial remission. The conditioning regimen was BEAM in 14 patients and other protocols with carmustine, etoposide and cyclophosphamide or melphalan in 5 patients.With a mean 26 months of follow-up, (8–66), the 5 year OS was 73.3% and EFS of 51.9%. 8/19 patients (42%) relapsed between 3 and 48 months after transplantation, the main cause of death was progressive disease. One patient died before day +100 with a severe fungal infection.This study group is too small to establish prognostic factors for relapse after transplantation, although is important for countries with limited resources to have data about local results. The OS and EFS in this group are similar to results in developed countries. Near 50% of patients with refractory or relapsed HD can be successfully treated with high dose chemotherapy and autologous stem cell rescue. It's important to have a longer follow up on these patients so we can perform analysis on prognostic factors for relapse and survival. Here we report a retrospective analysis performed to evaluate the results of autologous hematopoietic stem cell transplantation in pediatric patients with Hodgkin Disease (HD) in a single center in Bogota, Colombia. Nineteen patients with relapsed or refractory HD underwent autologous stem cell transplantation between 1998 and 2006. 8 female/11 male, with mean age of 10.9 years (7–14). At diagnosis patients were staged: I and IIA 10, IIB 1, IIIA 1, IIIB 4 and stage IV 6. The response to first line therapy was: 8 patients had failure to induction, and 6 early relapse (before 12 months). At transplantation: 10 patients were in 2nd complete remission, 2 in 3th complete remission and 7 were in partial remission. The conditioning regimen was BEAM in 14 patients and other protocols with carmustine, etoposide and cyclophosphamide or melphalan in 5 patients. With a mean 26 months of follow-up, (8–66), the 5 year OS was 73.3% and EFS of 51.9%. 8/19 patients (42%) relapsed between 3 and 48 months after transplantation, the main cause of death was progressive disease. One patient died before day +100 with a severe fungal infection. This study group is too small to establish prognostic factors for relapse after transplantation, although is important for countries with limited resources to have data about local results. The OS and EFS in this group are similar to results in developed countries. Near 50% of patients with refractory or relapsed HD can be successfully treated with high dose chemotherapy and autologous stem cell rescue. It's important to have a longer follow up on these patients so we can perform analysis on prognostic factors for relapse and survival.